Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics' grass pollen study running ahead of schedule

The Phase II study of its PQ Grass immunotherapy, an aluminium-free, ultra-short course hay fever treatment, is designed to evaluate dose response and safety
girl sneezing
The short-course injection offers the prospect of relief to the thousands who suffer badly with grass pollen allergy

Allergy Therapeutics PLC (LON:AGY) said the results of its Phase II clinical trial are due to be published ahead of expectations early in the second-half following the completion of patient recruitment.

The study of its PQ Grass immunotherapy, an aluminium-free, ultra-short course hay fever treatment, is designed to evaluate dose response and safety.

READ: Allergy Therapeutics expects first-half revenue rise; continues to take market share from rivals

In all, 440 people at 50 centres in Germany, Austria and Poland are taking part in the clinical assessment of the inoculation, the company said in a statement on Monday.

Big US market 

However, one of the key target markets for the PQ Grass is the US, where it would be the first immunotherapy injection to be registered and where peak grass vaccine sales could be US$300-$400mln a year.

Chief executive Manuel Llobet said: "The completion of recruitment for all patients in our phase II trial is an important step in our journey towards access to the US market in which PQ Grass has the potential to become a convenient, best in class, ultra-short course subcutaneous immunotherapy.

“We are pleased that the study is running ahead of schedule and look forward to seeing the results later this year."

The company has three growth ‘pillars’, which includes growing strongly in its European heartland where it has a robust, profitable business.

Three pillars 

It wants to do this by expanding its market share and making additional product registrations.

It has a strong pipeline of products coming through and investment in this regard will help underpin the bedrock of the business. This is growth pillar two.

The third is the US, which as the largest allergy market in the world, provides a significant opportunity. The environment there is changing, potentially driving new customers towards the firm’s products.

As mentioned above, the potential market size of the US could be transformational for Allergy Therapeutics as the graphic below reveals.

Allergy Therapeutics has an 80-year history and so is no “jam tomorrow” drug development company and was spun out of SmithKline Beecham in 1999.

No flash in the pan 

Headquartered in Worthing, West Sussex, it employs around 500 people.

Its most commonly prescribed vaccines are used to treat pollen-related allergies, particularly allergies to grasses and trees.

It has a strong presence in Europe, with established operations in Germany, Italy, Spain, Austria, Switzerland, the Netherlands and the United Kingdom, while in other markets it often makes its products available through distribution partners.

Its Pollinex Quattro vaccine for the treatment of seasonal allergic rhinitis (hay fever) from grass, tree or ragweed pollen allergy is already established in Europe.

View full AGY profile View Profile

Allergy Therapeutics PLC Timeline

Related Articles

mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use